Journal of Cardiac Failure
Volume 12, Issue 1 , Pages 1-9 , February 2006

The Year in Heart Failure 2005

  • Barry M. Massie, MD

      Affiliations

    • From the University of California, San Francisco
    • Corresponding Author InformationReprint requests: Barry M. Massie, MD, Cardiology Division (111C), San Francisco VAMC, 4150 Clement St., San Francisco, CA 94121.
    • ,
  • Thomas Force, MD

      Affiliations

    • Center for Translational Medicine Jefferson Medical College, Philadelphia, Pennsylvania

References 

  1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  3. Cleland JGF, Daubert J-C, Erdman E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and morality in heart failure. N Engl J Med. 2005;352:1539–1549
  4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  5. Moss AJ, Vyas A, Greenberg H, Case RB, Zareba W, Hall WJ, et al. Temporal aspects of improved survival with the implanted defibrillator (MADIT-II). Am J Cardiol. 2004;94:312–315
  6. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  7. Solomon SD, Zelenkafske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden cardiac death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;2581–2588
  8. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431
  9. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116–1143
  10. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart J. 2005;26:1115–1140
  11. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760–3765
  12. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–1480
  13. The ESCAPE Investigators . Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness. The ESCAPE trial. J Am Med Assoc. 2005;294:1625–1633
  14. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. J Am Med Assoc. 2005;294:1664–1670
  15. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  16. Cuffe MS, Cuffe RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  17. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) . Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;27:1531–1540
  18. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  19. Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes?. Circulation. 2005;111:1459–1461
  20. Topol EJ. Nesiritide—not verified. N Engl J Med. 2005;353:113–116
  21. Sackner-Bernstein J, Aaronson KD. Nesiritide—not verified. [Letter] N Engl J Med. 2005;353:1525–1527
  22. Schreiner G. Nesiritide—not verified. [Letter] N Engl J Med. 2005;353:1525–1527
  23. Topol EJ. Nesiritide—not verified. [Response to letters] N Engl J Med. 2005;353:1525–1527
  24. Wang DJ, Dowling TC, Meadows D. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625
  25. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514–1517
  26. Nesiritide [package insert]. Available at http://www.natrecor.com/pdf/natrecor_pi.pdf. Accessed January 6, 2006.
  27. April PA. Nesiritide—not verified. [Letter] N Engl J Med. 2005;353:1525–1527
  28. MedWatch Safety Alert: Natrecor (nesiritide). Available at: http://www.fda.gov/medwatch/safety/2005/natrecor2_DHCP.htm. Accessed December 26, 2005.
  29. McMurray JV, Teerlink JR, Bourge B, et al. Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies (VERITAS): two multi-center, double-blind, placebo-controlled, parallel-group trials assessing the efficacy, safety, and tolerability of tezosentan in acute heart failure. Presented at: American College of Cardiology Annual Scientific Session; March 2005.
  30. Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J. Randomized Evaluations of Levosimendan (REVIVE-II). Presented at: American Heart Association Annual Scientific Session; November 2005.
  31. Mebazaa A, Alain Cohen-Solal, Kleber F, et al. Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE). Presented at: American Heart Association Annual Scientific Session; November 2005.
  32. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047–2051
  33. Bart BA, Boyle A, Bank AJ, Anand I, Anand I, Olivari MT, et al Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–2046
  34. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation. 2004;110:3518–3526
  35. Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol. 2005;45:1654–1664
  36. Gesica Investigators . Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ. 2005;33:425
  37. Abraham WT, Trupp RJ, Mehra MR, et al. Prospective Evaluation and Identification of Decompensation by ICG Test (PREDICT). Presented at: Heart Failure Society of America 8th Annual Scientific Meeting; September 13, 2004.
  38. Abraham W, Foreman B, Fishel R, Odyrzynski N. Clinical value of measuring intra-thoracic impedance in patients with chronic heart failure—Fluid Accumulation Status Trial (FAST). [Abstract] JACC. 2005;45:153A–154A
  39. Bourge R, Abraham WT, Aaron MF. Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF): ambulatory hemodynamic guided management of heart failure. Presented at: American College of Cardiology Annual Scientific Session 2005; March 6–9, 2005; Orlando, FL: Late Breaking Clinical Trials II.
  40. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:249–257
  41. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225
  42. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426–2435
  43. Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, et al. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005;11:659–669
  44. Metra M. ESSENTIAL: the Studies of Oral Enoximone Therapy in Advanced Heart Failure. Presented at: European Society of Cardiology Congress 2005; September 5–8, 2005, Stockholm, Sweden: Late Breaking Clinical Trials.
  45. Feldman AM. EMOTE: Oral enoximone in intravenous inotrope dependent subjects. Presented at: Heart Failure Society of America 8th Annual Scientific Meeting, September 13, 2004, Toronto, Canada; Late-Breaking Clinical Trials.
  46. Press release reportingresults of OPT-CHF trial. Available online at: http://www.bcbiotech.ca/News/Member_Press_Releases/pr08150504.asp. Accessed December 28, 2005.
  47. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353:2025–2033
  48. Mann D. Results of a multicenter randomized clinical trial for the assessment of a cardiac support device (CSD) in patients with heart failure. Presented at: American Heart Association Scientific Sessions 2004; November 7–10, 2004, New Orleans.
  49. Feldman AM, Silver MA, Francis GS, De Lame PA, Parmley WW. Treating heart failure with enhanced external counterpulsation (EECP): design of the Prospective Evaluation of EECP in Heart Failure (PEECH) trial. J Card Fail. 2005;11:240–245
  50. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763–776
  51. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100:12313–12318
  52. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95:911–921
  53. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, et al. CD31– but not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res. 2005;97:52–61
  54. Mouquet F, Pfister O, Jain M, Oikonomopoulos A, Ngoy S, Summer R, et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow–derived stem cells. Circ Res. 2005;97:1090–1092
  55. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647–653
  56. Urbanek K, Rota M, Cascapera S, et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res. 2005;87:663–673
  57. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. Lancet. 2004;364:141–148
  58. Erbs S, Linke A, Adams V, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res. 2005;97:756–762
  59. Hambrecht R, Erbs S, Thiele H, et al. Intracoronary transplantation of circulating progenitor cells after normalization of chronic coronary artery occlusions: Long term effects on left ventricular function. [Abstract] Circulation. 2005;112(Suppl II):II–581
  60. Schachinger V. Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction: a randomized, double-blind, placebo-controlled multicenter trial (REPAIR-AMI). Late-breaking clinical trial presented at: American Heart Association Annual Scientific Session, November 2005.
  61. Lunde K. The effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction: the ASTAMI Randomized Controlled Trial. Late-breaking clinical trial presented at: American Heart Association Annual Scientific Session, November 2005.
  62. McNamara D. The A-HeFT pharmacogenomic analysis. Late-breaking trial presented at: Heart Failure Society of America Annual Meeting, September 2005.

PII: S1071-9164(06)00003-0

doi: 10.1016/j.cardfail.2006.01.001

Journal of Cardiac Failure
Volume 12, Issue 1 , Pages 1-9 , February 2006

Article Tools